Home » Posts tagged with » Boehringer Ingelheim
Boehringer Ingelheim expands pets vaccines production facility in Athens

Boehringer Ingelheim expands pets vaccines production facility in Athens

German pharma giant Boehringer Ingelheim has wrapped up the $76 million expansion of its pets vaccines production facility at Athens in Georgia, US. The investment doubles the capacity of Boehringer Ingelheim to produce vaccines for pets in the US and across the world two times. Expansion of the pets vaccines production plant was announced in […]

Boehringer Ingelheim, Inflammasome to advance new therapies for retinal diseases

German pharma giant Boehringer Ingelheim has entered into a co-development and license agreement with US-based Inflammasome Therapeutics to develop new retinal disease therapies and reduce the patient burden for eye diseases. The company is planning to develop up to three therapies for patients with retinal diseases by integrating its retinal disease pipeline portfolio compounds with […]

Continue reading …
Boehringer Ingelheim bags Ofev FDA approval for SSc-ILD

Ofev FDA approval for SSc-ILD : The US Food and Drug Administration (FDA) has extended approval for Boehringer Ingelheim Pharmaceuticals’ Ofev (nintedanib) capsules for the treatment of a particular condition associated with systemic sclerosis or scleroderma. The latest FDA approval for Ofev is for its use in slowing the rate of decline in pulmonary function […]

Continue reading …
Boehringer Ingelheim to initiate phase 2 trial of BI 456906 in obesity, diabetes

German drugmaker Boehringer Ingelheim will initiate Phase 2 clinical trial of dual-acting GLP-1/glucagon agonist BI 456906 in obesity and diabetes in late 2019. The compound in-licensed from Zealand Pharma is derived from the natural gut hormone oxyntomodulin and activates both the GLP-1 and glucagon receptors to control metabolic activities. The dual agonist BI 456906 with […]

Continue reading …
Boehringer Ingelheim, MD Anderson to advance new cancer treatments

German pharmaceutical giant Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center are joining forces to form a new virtual research and development center (R&D center) to rapidly advance new cancer treatments, covering various forms of the disease including lung and gastrointestinal cancers. The new virtual R&D center is expected to facilitate the […]

Continue reading …
Boehringer Ingelheim secures Ofev FDA approval recommendation for SSc-ILD

Ofev FDA approval recommendation: The US FDA’s Arthritis Advisory Committee has recommended approval of Boehringer Ingelheim’s kinase inhibitor Ofev (nintedanib) for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). The committee’s Ofev FDA approval recommendation was driven by the findings of the phase 3 SENSCIS trial, held in patients with SSc-ILD, a disease for […]

Continue reading …
Boehringer Ingelheim acquires Swiss biotech company AMAL Therapeutics

Boehringer Ingelheim acquisition of AMAL Therapeutics : German pharma company Boehringer Ingelheim has acquired Swiss biotech company AMAL Therapeutics for up to EUR325 million, as per the latest pharma acquisition news. AMAL Therapeutics, which was spun out from the University of Geneva in 2012, is focused on cancer immunotherapy and is engaged in advancing therapeutic […]

Continue reading …
Boehringer Ingelheim acquires oncolytic virus company ViraTherapeutics

German pharma company Boehringer Ingelheim has exercised its option to acquire 100% of Austria-based oncolytic virus company ViraTherapeutics for €210 million in a move to develop next generation viral-based immuno-oncology therapies. In September 2016, Boehringer Ingelheim and ViraTherapeutics entered into a long term collaboration to develop the oncolytic virus therapy platform and also to investigate […]

Continue reading …
Humira biosimilar Cyltezo meets objective in phase 3 plaque psoriasis trial

German pharma company Boehringer Ingelheim said that Cyltezo, a biosimilar to AbbVie psoriasis drug Humira, achieved clinical equivalence to the reference product in a phase 3 trial in patients with moderate-to-severe chronic plaque psoriasis. Cyltezo succeeded in the NCT 02850965 phase 3 trial by not showing any clinically meaningful differences in efficacy, safety and immunogenicity […]

Continue reading …